Etripamil

Next Previous
Drug Profile

Etripamil

Alternative Names: (-)-MSP-2017; MSP-2017; MSP-2017A; MSP-2017B

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Milestone Pharmaceuticals
  • Class Antiarrhythmics; Benzoates; Esters; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Paroxysmal supraventricular tachycardia
  • No development reported Angina pectoris

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Paroxysmal-supraventricular-tachycardia(In volunteers) in Australia (Intranasal, Spray)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Angina-pectoris in Canada (Intranasal, Spray)
  • 11 May 2017 Milestone Pharmaceuticals plans the NODE-301 phase III trial for Paroxysmal supraventricular tachycardia in USA, in June 2018 (NCT03464019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top